Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 410

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Open access
Edalatifard, Maryam, Akhtari, Maryam, Salehi, Mohammadreza, Naderi, Zohre, Jamshidi, Ahmadreza, Mostafaei, Shayan, Najafizadeh, Seyed Reza, Farhadi, Elham, Jalili, Nooshin, Esfahani, Masoud, Rahimi, Besharat, Kazemzadeh, Hossein, Mahmoodi Aliabadi, Maedeh, Ghazanfari, Tooba, Sattarian, Mohammadreza, Ebrahimi Louyeh, Hourvash, Raeeskarami, Seyed Reza, Jamalimoghadamsiahkali, Saeidreza, Khajavirad, Nasim, Mahmoudi, Mahdi, Rostamian, Abdolrahman · 2020 · European Respiratory Journal

Abstract

Introduction: There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients. Methods: We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day−1 for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population. Results: 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%versus 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9%versus 42.9%; p<0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p<0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study. Conclusions: Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02808-2020

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 410

Metadata

Authors
Edalatifard, M., Akhtari, M., Salehi, M., Naderi, Z., Jamshidi, A., Mostafaei, S., Najafizadeh, S. R., Farhadi, E., Jalili, N., Esfahani, M., Rahimi, B., Kazemzadeh, H., Mahmoodi Aliabadi, M., Ghazanfari, T., Sattarian, M., Ebrahimi Louyeh, H., Raeeskarami, S. R., Jamalimoghadamsiahkali, S., Khajavirad, N., Mahmoudi, M., & Rostamian, A.
Venue
European Respiratory Journal
Published
2020-09-17
Volume
56
Issue
6
Pages
2002808
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3087214787
Cited by
410
References
28
FWCI
10.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. https://app.cochat.ai/papers/10.1183/13993003.02808-2020
The paper
Edalatifard, M., Akhtari, M., Salehi, M., Naderi, Z., Jamshidi, A., Mostafaei, S., Najafizadeh, S. R., Farhadi, E., Jalili, N., Esfahani, M., Rahimi, B., Kazemzadeh, H., Mahmoodi Aliabadi, M., Ghazanfari, T., Sattarian, M., Ebrahimi Louyeh, H., Raeeskarami, S. R., Jamalimoghadamsiahkali, S., Khajavirad, N., . . . Rostamian, A. (2020). Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal. https://doi.org/10.1183/13993003.02808-2020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.